TrialSignal
Clinical trial intelligence report
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Subjects With Advanced Breast Cancer
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT00321464
Status
COMPLETED
Phase
PHASE3
Sponsor
Amgen
Executive brief
Investment-Ready Snapshot
This clinical trial, sponsored by Amgen and in collaboration with Daiichi Sankyo, aimed to compare the efficacy of Denosumab against Zoledronic Acid in treating bone metastases in patients with advanced breast cancer. The study enrolled 2049 participants and was completed in April 2012.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00321464
Indication
Bone Metastases
Modality
monoclonal antibody
Target
Denosumab, Zoledronic Acid
Intervention
Denosumab, Zoledronic Acid
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.